|
Randomized Trial of Avelumab Plus Cetuximab vs Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (A091802) |
II |
|
|
Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer (S1806) |
III |
|
|
Randomized Trial of Erlotinib vs Placebo in Patients with Completely Resected EGFR Mutant NonSmall Cell Lung Cancer (A081105) |
III |
|
|
Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706) |
II |
|
|
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (A021502) |
III |
|
|
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients who Smoke Cigarettes (A221401) |
|
|
|
Registry for Lung Screening Excellence |
|
|
|
Study Comparing Tislelizumab + Platinum And Fluoropyrimidine Versus Placebo Plus Platinum And Fluoropyrimidine As First-Line Treatment In Patients With Locally Advanced Unresectable Or Metastatic Gastric or GEJ Adenocarcinoma (BGBA317- 305) |
III |
|
|
Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress1) |
III |
|
|
Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer; (AFT-19) |
III |
|
|
Study of FOLFIRINOX plus Ramucirumab versus FOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients (GI14-198) |
II |
|
|
Study Of High Dose Interleukin 2 Vs High Dose Interleukin 2 Plus Entinostat In Untreated Advanced Renal Cell Carcinoma (HCRN GU17-289) |
II |
|
|
Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors (PCYC-1128-CA) |
I |
|
|
Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (MEL 16-252 SALVO) |
II |
|
|
Study of mFolfox6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatci Colorectal Cancer (GI004) |
III |
|
|
Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer (EA2165) |
II |
|
|
Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low Blast Acute Myelogenous Leukemia(Pevonedistat-3001) |
III |
|
|
Study Testing the Addition of Nivolumab Pre and Post Nephrectomy in Patients with Renal Cell Carcinoma (EA8143) |
III |
|
|
The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (CONNECT) |
III |
|
|
Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (SUMMIT) |
|
|
|
Treatment Resistance Following AntiCancer Therapies (18150) |
|
|
|
Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CRLA-4 and Anti-PD-1 Blockade in Rare Tumors) (S1609) |
|
|
|
Trial Comparing Paclitaxel, Ifosfamide, and Cisplatin with High-Dose Chemo Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors (A031102) |
III |
|
|
Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (DT001) |
I |
|
|
Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (GU006) |
II |
|
